Lisa S. Wang, MD - PIH Health | LinkedIn

Dr. Lisa S. Wang

Claim this profile

Presbyterian Intercommunity Hospital

Studies Lung Cancer
Studies Breast Cancer
22 reported clinical trials
51 drugs studied

Area of expertise

1

Lung Cancer

Lisa S. Wang has run 8 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage I
2

Breast Cancer

Lisa S. Wang has run 7 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2

Affiliated Hospitals

Image of trial facility.

Presbyterian Intercommunity Hospital

Image of trial facility.

PIH Health

Clinical Trials Lisa S. Wang is currently running

Image of trial facility.

Disitamab Vedotin + Pembrolizumab vs Chemotherapy

for Bladder Cancer

This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.

Recruiting

2 awards

Phase 3

Image of trial facility.

GLSI-100

for HER2 Positive Breast Cancer

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A\*02 positive and HER2/neu positive subjects.

Recruiting

1 award

Phase 3

6 criteria

More about Lisa S. Wang

Clinical Trial Related

4 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Lisa S. Wang has experience with

  • Pembrolizumab
  • Abemaciclib
  • Placebo
  • Gemcitabine
  • Pemetrexed
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Lisa S. Wang specialize in?

Is Lisa S. Wang currently recruiting for clinical trials?

Are there any treatments that Lisa S. Wang has studied deeply?

What is the best way to schedule an appointment with Lisa S. Wang?

What is the office address of Lisa S. Wang?

Is there any support for travel costs?